弥漫性大B细胞淋巴瘤一线免疫化疗后复发/难治的分子遗传学因素研究进展

Advances in molecular genetic factors of relapse/refractory diffuse large B-cell lymphoma after first-line immunochemotherapy

弥漫性大B细胞淋巴瘤具有高度异质性,不同个体的临床特征、遗传学改变、免疫表型等存在差异,对免疫化疗方案的反应也不相同。多数弥漫性大B细胞淋巴瘤患者一线应用R-CHOP(利妥昔单抗+环磷酰胺+多柔比星+长春新碱+泼尼松)方案治疗可获得长期生存,但30%~40%的患者出现复发/难治。本研究就弥漫性大B细胞淋巴瘤的分子分型、一线免疫化疗后复发/难治相关基因突变的研究进展作一综述。

Diffuse large B-cell lymphoma is a highly heterogeneous tumor with different clinical features,genetic changes,immunophenotypes,and responses to immunochemotherapy regimen.The first-line treatment with R-CHOP(rituximab+cyclophosphamide+doxorubicin+vinnestine+prednisone)can achieve a long survival in most patients with diffuse large B-cell lymphoma,but relapse/refractory would develop in 30%to 40%of patients.This paper reviews the research progress of the molecular typing of diffuse large B-cell lymphoma and the progress of relapse/refractory related gene mutations after first-line immunochemotherapy.